175 related articles for article (PubMed ID: 28076825)
21. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
22. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.
Li Z; Xu X; Liu R; Deng F; Zeng X; Zhang L
Bioorg Med Chem; 2018 Aug; 26(15):4560-4566. PubMed ID: 30082106
[TBL] [Abstract][Full Text] [Related]
27. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
[TBL] [Abstract][Full Text] [Related]
30. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Wang X; Xu X; Yang J; Qiu Q; Qiang H; Huang W; Qian H
Bioorg Med Chem; 2015 Oct; 23(20):6666-72. PubMed ID: 26420383
[TBL] [Abstract][Full Text] [Related]
33. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
35. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
[TBL] [Abstract][Full Text] [Related]
37. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.
Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W
Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]